# Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Study · id `cardio:ct-nct05661552` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05661552](<https://clinicaltrials.gov/study/NCT05661552>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05661552

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT05661552. Randomized; no masking; primary purpose treatment. Start 2022-12-01 (actual); primary completion 2025-02-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT05661552, source copy `cardio:ctgov-nct05661552-2025-03-13`, retrieved 2026-10-31)
- Started: 2022-12-01 (actual) (ClinicalTrials.gov record NCT05661552, source copy `cardio:ctgov-nct05661552-2025-03-13`, retrieved 2026-10-31)
- Primary completion: 2025-02-05 (actual) (ClinicalTrials.gov record NCT05661552, source copy `cardio:ctgov-nct05661552-2025-03-13`, retrieved 2026-10-31)
- Completion: 2025-02-05 (actual) (ClinicalTrials.gov record NCT05661552, source copy `cardio:ctgov-nct05661552-2025-03-13`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT05661552, source copy `cardio:ctgov-nct05661552-2025-03-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05661552-2025-03-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
- Acronym: C-STAR
- Condition: Low-Density-Lipoprotein-Type \[LDL\] Hyperlipoproteinemia
- Intervention (Drug): Evolocumab 140 MG/ML
- Intervention (Drug): Rosuvastatin 5mg
- Intervention (Drug): Ezetimibe 10mg
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER
- Collaborator: Daewoong Pharmaceutical Co. LTD.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)
- Registry lists this organization as a collaborator: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 0e575dcf41fed5a1970732512208a51d8d1cc0ac7e1fc0d92f629ec2653ade96
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
